Focus on CMV
Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.
News
Challenge experiments successfully finalized
Schlieren, 10 May 2012
The challenge experiment using Redbiotec’s tetravalent influenza VLPs was successfully finalized. Results obtained clearly show that influenza VLPs are capable of stimulating the humoral and cellular immune responses which neutralize and inhibit replication of a challenge virus. When immunized mice were challenged with a lethal dose of the parental virus, 100% of mice were protected.
Redbiotec signs feasibility study with 4-Antibody AG
Schlieren, 17 February 2012
Redbiotec is pleased to announce that it has entered into a collaboration with 4-Antibody, in which Redbiotec will apply its proprietary technology platform rePAX™ to an undisclosed discovery area. This agreement is a further validation of the application of Redbiotec’s VLPs in antibody generation.
More children have disabilities due to congenital CMV than genetic disorders (Down syndrome).
Learn more about our proprietary rePAXTM technology.
Find our newest scientific publications here.
Meet us at one of our upcoming events.